{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:14:42Z","timestamp":1791173682839,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,1,6]],"date-time":"2015-01-06T00:00:00Z","timestamp":1420502400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s40262-014-0224-4","type":"journal-article","created":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T13:44:45Z","timestamp":1420465485000},"page":"133-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":155,"title":["Clinical and Preclinical Pharmacokinetics and Pharmacodynamics of Mipomersen (Kynamro\u00ae): A Second-Generation Antisense Oligonucleotide Inhibitor of Apolipoprotein B"],"prefix":"10.1007","volume":"54","author":[{"given":"Richard S.","family":"Geary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda F.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley T.","family":"Crooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,6]]},"reference":[{"key":"224_CR1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259\u201393.","journal-title":"Annu Rev Pharmacol Toxicol."},{"key":"224_CR2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1201\/9780849387951","volume-title":"Antisense drug technology: principles, strategies, and applications","author":"ST Crooke","year":"2007","unstructured":"Crooke ST, Vickers T, Lima W, et al. Mechanisms of antisense drug action, an introduction. In: Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. 2nd ed. Boca Raton: CRC Press; 2007. p. 3\u201346.","edition":"2"},{"key":"224_CR3","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","volume":"279","author":"H Wu","year":"2004","unstructured":"Wu H, Lima WF, Zhang H, et al. Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem. 2004;279:17181\u20139.","journal-title":"J Biol Chem."},{"key":"224_CR4","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/78475","volume":"18","author":"H Zhang","year":"2000","unstructured":"Zhang H, Cook J, Nickel J, et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol. 2000;18:862\u20137.","journal-title":"Nat Biotechnol."},{"key":"224_CR5","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bcp.2008.11.005","volume":"77","author":"RZ Yu","year":"2009","unstructured":"Yu RZ, Lemonidis KM, Graham MJ, et al. Cross-species comparison of in vivo PK\/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol. 2009;77:910\u20139.","journal-title":"Biochem Pharmacol."},{"key":"224_CR6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2533\/chimia.1996.168","volume":"50","author":"KH Moser Altmann","year":"1996","unstructured":"Moser Altmann KH, Dean NM, Fabbro D, et al. Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals. Chimia. 1996;50:168\u201376.","journal-title":"Chimia."},{"key":"224_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1388-1981(99)00083-9","volume":"1440","author":"RA Davis","year":"1999","unstructured":"Davis RA. Cell and molecular biology of the assembly and secretion of apolipoprotein B-containing lipoproteins by the liver. Biochim Biophys Acta. 1999;1440:1\u201331.","journal-title":"Biochim Biophys Acta."},{"key":"224_CR8","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","volume":"60","author":"BA Ference","year":"2012","unstructured":"Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631\u20139.","journal-title":"J Am Coll Cardiol."},{"key":"224_CR9","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","volume":"307","author":"SM Boekholdt","year":"2012","unstructured":"Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302\u20139.","journal-title":"JAMA."},{"key":"224_CR10","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet."},{"key":"224_CR11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"SM Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227\u201339.","journal-title":"Circulation."},{"key":"224_CR12","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacl.2011.03.001","volume":"5","author":"AC Goldberg","year":"2011","unstructured":"Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:133\u201340.","journal-title":"J Clin Lipidol."},{"key":"224_CR13","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.atherosclerosis.2012.02.019","volume":"223","author":"FJ Raal","year":"2012","unstructured":"Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262\u20138.","journal-title":"Atherosclerosis."},{"key":"224_CR14","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","volume":"124","author":"FJ Raal","year":"2011","unstructured":"Raal FJ, Pilcher GJ, Panz VR, et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation. 2011;124:2202\u20137.","journal-title":"Circulation."},{"key":"224_CR15","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation. 2014;129:1022\u201332.","journal-title":"Circulation."},{"key":"224_CR16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jacl.2013.09.004","volume":"8","author":"WV Brown","year":"2014","unstructured":"Brown WV, Rader DJ, Goldberg AC. JCL roundtable: drug treatment of severe forms of familial hypercholesterolemia. J Clin Lipidol. 2014;8:10\u20137.","journal-title":"J Clin Lipidol."},{"key":"224_CR17","unstructured":"Genyzme Corporation. KYNAMRO\u00ae (mipomersen sodium) injection prescribing information. 2013. Available from: http:\/\/www.kynamro.com\/~\/media\/Kynamro\/Files\/KYNAMRO-PI.pdf . Accessed 6 Jun 2014."},{"key":"224_CR18","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998\u20131006.","journal-title":"Lancet."},{"issue":"3","key":"224_CR19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCOUTCOMES.110.959247","volume":"4","author":"AD Sniderman","year":"2011","unstructured":"Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011;4(3):337\u201345.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"224_CR20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jacc.2012.04.038","volume":"60","author":"S Tsimikas","year":"2012","unstructured":"Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease. J Am Coll Cardiol. 2012;60:716\u201321.","journal-title":"J Am Coll Cardiol."},{"key":"224_CR21","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/01.ATV.20.2.522","volume":"20","author":"HG Kraft","year":"2000","unstructured":"Kraft HG, Lingenhel A, Raal FJ, Hohenegger M, Utermann G. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2000;20:522\u20138.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"224_CR22","first-page":"183","volume-title":"Antisense drug technology: principles, strategies, and applications","author":"AA Levin","year":"2007","unstructured":"Levin AA, Yu RZ, Geary RS. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. 2nd ed. Boca Raton: CRC Press; 2007. p. 183\u2013216.","edition":"2"},{"key":"224_CR23","first-page":"305","volume-title":"Antisense drug technology: principles, strategies, and applications","author":"RS Geary","year":"2007","unstructured":"Geary RS, Yu RZ, Siwkowski A, et al. Pharmacokinetic\/pharmacodynamic properties of phosphorothioate 2\u2032-O-(2-methoxyethyl)-modified antisense oligonucleotides in animal and man. In: Crooke ST, editor. Antisense drug technology: principles, strategies, and applications. 2nd ed. Boca Raton: CRC Press; 2007. p. 305\u201326.","edition":"2"},{"key":"224_CR24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","volume":"5","author":"RS Geary","year":"2009","unstructured":"Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2009;5:381\u201391.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"224_CR25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1517\/17425255.2013.737320","volume":"9","author":"RZ Yu","year":"2013","unstructured":"Yu RZ, Grundy JS, Geary RS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol. 2013;9:169\u201382.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"224_CR26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2125.2012.04469.x","volume":"76","author":"ST Crooke","year":"2013","unstructured":"Crooke ST, Geary RS. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br J Clin Pharmacol. 2013;76:269\u201376.","journal-title":"Br J Clin Pharmacol."},{"issue":"3","key":"224_CR27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","volume":"35","author":"RZ Yu","year":"2007","unstructured":"Yu RZ, Kim TW, Hong A, et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos. 2007;35(3):460\u20138.","journal-title":"Drug Metab Dispos."},{"key":"224_CR28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/oli.2010.0252","volume":"20","author":"M Baek","year":"2010","unstructured":"Baek M, Yu RZ, Gaus H, Grundy JS, Geary RS. In vitro metabolic stabilities and metabolism of 2\u2032-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in reincubated rat or human whole liver homogenates. Oligonucleotides. 2010;20:309\u201316.","journal-title":"Oligonucleotides."},{"key":"224_CR29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/0003088-200948010-00003","volume":"48","author":"RZ Yu","year":"2009","unstructured":"Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2\u2032-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet. 2009;48:39\u201350.","journal-title":"Clin Pharmacokinet."},{"key":"224_CR30","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","volume":"114","author":"JJ Kastelein","year":"2006","unstructured":"Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114:1729\u201335.","journal-title":"Circulation."},{"key":"224_CR31","doi-asserted-by":"crossref","first-page":"e000560","DOI":"10.1161\/JAHA.113.000560","volume":"3","author":"JD Flaim","year":"2014","unstructured":"Flaim JD, Grundy JS, Baker BF, et al. Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J Am Heart Assoc. 2014;3:e000560.","journal-title":"J Am Heart Assoc."},{"key":"224_CR32","doi-asserted-by":"crossref","first-page":"314","DOI":"10.5414\/CP201975","volume":"52","author":"Z Li","year":"2014","unstructured":"Li Z, Hard ML, Andersen G, et al. Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects. Int J Clin Pharmacol Ther. 2014;52:314\u201320.","journal-title":"Int J Clin Pharmacol Ther."},{"key":"224_CR33","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1093\/eurheartj\/ehr148","volume":"32","author":"F Akdim","year":"2011","unstructured":"Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J. 2011;32:2650\u20139.","journal-title":"Eur Heart J."},{"key":"224_CR34","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jacc.2009.11.069","volume":"55","author":"F Akdim","year":"2010","unstructured":"Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55:1611\u20138.","journal-title":"J Am Coll Cardiol."},{"key":"224_CR35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.amjcard.2010.01.003","volume":"105","author":"F Akdim","year":"2010","unstructured":"Akdim F, Visser ME, Tribble DL, et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413\u20139.","journal-title":"Am J Cardiol."},{"key":"224_CR36","doi-asserted-by":"crossref","first-page":"e49006","DOI":"10.1371\/journal.pone.0049006","volume":"7","author":"MP McGowan","year":"2012","unstructured":"McGowan MP, Tardif JC, Ceska R, et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One. 2012;7:e49006.","journal-title":"PLoS One."},{"key":"224_CR37","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1161\/CIRCULATIONAHA.112.104125","volume":"126","author":"EA Stein","year":"2012","unstructured":"Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126:2283\u201392.","journal-title":"Circulation."},{"key":"224_CR38","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","volume":"62","author":"GS Thomas","year":"2013","unstructured":"Thomas GS, Cromwell WC, Ali S, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2013;62:2178\u201384.","journal-title":"J Am Coll Cardiol."},{"key":"224_CR39","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell TA 3rd, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112:1479\u201390.","journal-title":"Circ Res."},{"key":"224_CR40","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1038\/mtna.2012.44","volume":"1","author":"NR Jones","year":"2012","unstructured":"Jones NR, Pegues MA, McCrory MA, Singleton W, Bethune C, Baker BF, Norris DA, Crooke RM, Graham MJ, Szalai AJ. A selective inhibitor of human C-reactive protein translation is efficacious in vitro and in C-reactive protein transgenic mice and humans. Mol Ther Nucleic Acids. 2012;1:e52. doi: 10.1038\/mtna.2012.44 .","journal-title":"Mol Ther Nucleic Acids."},{"key":"224_CR41","doi-asserted-by":"crossref","unstructured":"Santos RD, Duell PB, East C, et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. Epub 23 Dec 2013.","DOI":"10.1093\/eurheartj\/eht549"},{"key":"224_CR42","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/FJC.0000000000000101","volume":"64","author":"Z Li","year":"2014","unstructured":"Li Z, Hard ML, Grundy JS, et al. Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen. J Cardiovasc Pharmacol. 2014;64:164\u201371.","journal-title":"J Cardiovasc Pharmacol."},{"key":"224_CR43","first-page":"S23","volume":"95","author":"Z Li","year":"2014","unstructured":"Li Z, Yu R, Hard M, et al. The second generation antisense oligonucleotide (ASO) mipomersen does not prolong QT interval in a thorough QT\/QTC study in healthy subjects. Clin Pharm Ther. 2014;95:S23.","journal-title":"Clin Pharm Ther."},{"key":"224_CR44","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1194\/jlr.M400492-JLR200","volume":"46","author":"RM Crooke","year":"2005","unstructured":"Crooke RM, Graham MJ, Lemonidis KM, et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res. 2005;46:872\u201384.","journal-title":"J Lipid Res."},{"key":"224_CR45","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1201\/9780849387951","volume-title":"Antisense drug technology principles, strategies, and applications","author":"RM Crooke","year":"2007","unstructured":"Crooke RM, Baker BF, Wedel MK. Cardiovascular therapeutic applications. In: Crooke ST, editor. Antisense drug technology principles, strategies, and applications. 2nd ed. Boca Raton: CRC Press; 2007. p. 601\u201339.","edition":"2"},{"key":"224_CR46","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1093\/eurheartj\/ehs023","volume":"33","author":"ME Visser","year":"2012","unstructured":"Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33:1142\u20139.","journal-title":"Eur Heart J."},{"key":"224_CR47","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jacl.2013.03.080","volume":"7","author":"PB Duell","year":"2013","unstructured":"Duell PB, Rose JE, Selvey S, et al. Long term efficacy and safety of mipomersen during 4\u00a0years of treatment in a cohort of patients with heterozygous familial hypercholesterolemia and coronary artery disease (CAD). J Clin Lipidology. 2013;7:276.","journal-title":"J Clin Lipidology."},{"key":"224_CR48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacl.2014.02.056","volume":"8","author":"S Selvey","year":"2014","unstructured":"Selvey S, Raal FJ. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces LDL-C in HoFH pediatric patients. J Clin Lipidol. 2014;8:330.","journal-title":"J Clin Lipidol."},{"key":"224_CR49","unstructured":"Yu R, Geary R, Kim T, Levin AA. Mouse and monkey toxicokinetics of a second generation antisense oligonucleotide (ASO) targeting human apoB-100, following chronic treatment for up to 1\u00a0year [abstract no. T2492]. In: Annual Meeting of American Association of Pharmaceutical Scientists; 11\u201315 November 2007; San Diego (CA)."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-014-0224-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0224-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-014-0224-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T23:47:30Z","timestamp":1650930450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-014-0224-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,6]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["224"],"URL":"https:\/\/doi.org\/10.1007\/s40262-014-0224-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,6]]}}}